Table 3.
Summary of antibody treatment strategies.
| Treatment | Mechanism Target | Clinical benefit? | Mortality decrease? |
|---|---|---|---|
| Convalescent Plasma | Polyclonal Abs against SARS-CoV-2 | Mixed | X |
| Itolizumab | mAb against CD-6- attenuates T-cell costimulation | ✓* | X* |
| Tocilizumab | mAb against IL-6 receptor | X | X |
| Etesevimab | mAb against the receptor-binding domain of the spike protein | ✓ | ✓ |
| Bamlanivimab | mAb against the receptor-binding domain of the spike protein | ✓ | ✓ |
✓ - The drug produced the respective column’s effect. X - The drug failed to produce the respective column’s effect. Mixed - The drug produced negative and positive outcomes. *- Clinical trials of this drug either failed to exceed 100 participants or lacked any blinding.